PHAS - PhaseBio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.01
-0.01 (-0.17%)
At close: 4:00PM EDT

6.02 +0.01 (0.17%)
After hours: 7:55PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.02
Open6.00
Bid5.99 x 800
Ask6.18 x 1000
Day's Range5.51 - 6.09
52 Week Range2.60 - 14.08
Volume1,885,779
Avg. Volume659,158
Market Cap172.974M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateMay 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    P/E Ratio Insights for PhaseBio Pharmaceuticals

    Looking into the current session, PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares are trading at $6.14, after a 38.91% increase. Moreover, over the past month, the stock increased by 59.3%, but in the past year, fell by 42.42%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.The stock is currently above from its 52 week low by 136.15%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 7.24 in the Biotechnology industry, PhaseBio Pharmaceuticals Inc. has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * Stocks That Hit 52-Week Highs On Thursday * Price Over Earnings Overview: ARCA biopharma * Golar LNG: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • TheStreet.com

    PhaseBio Cleared by FDA for Trial of Virus Treatment

    PhaseBio was cleared by the FDA to conduct a clinical trial to assess a drug candidate to treat covid-19.

  • The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
    Benzinga

    The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) * ADC Therapeutics SA (NYSE: ADCT) (went public May 15) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * argenx SE - ADR (NASDAQ: ARGX) * ChemoCentryx Inc (NASDAQ: CCXI) * Imara Inc NASDAQ: (IMRA) * Immunovant Inc (NASDAQ: IMVT) * Mersana Therapeutics Inc (NASDAQ: MRSN) (announced positive interim Phase 1 data for XMT-1536 in patients with ovarian cancer) * Vermillion, Inc. (NASDAQ: VRML)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 27) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (announced publication of positive data for its antibiotic in treating bacteremia and endocarditis) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)Stocks In Focus PhaseBio Gets FDA Nod For Potentially Pivotal Trial Of COVID-19 Treatment PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome.PhaseBio said it expects to begin dosing patients by the end of June and report trial results late in the fourth quarter of 2020.The stock was jumping 54.3% to $6.82 in Thursday's premarket session.Roche To Commence Late-Stage Study Of COVID-19 Combo Treatment Option With Gilead's Remdesivir Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced the initiation of a global Phase 3 study to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (NASDAQ: GILD).Roche aid it expects to enroll patients in the study in June, with the results likely to be available in the summer.Separately, Roche announced European approval of a new, shorter 2-hour Ocrevus infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis.Tetraphase Receives Sweetened Offer From Melinta After AcelRx's Revised Offer Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said its board has received a revised proposal from Melinta amending its prior acquisition proposal. In light of the amended offer, Tetrephase said the Melinta offer is a superior offer.Tetraphase said it has notified AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) of the amended Melinta proposal, the superior offer determination and its intention to consider changing its recommendation or terminating the AcelRx offer unless AcelRx proposes revisions to the terms on or prior to Monday, June 1.This follows AccelRx sweetening its earlier offer to $30 million in stock and cash based on the AcelRx closing share price on May 22, plus an additional $14.5 million in contingent value rights payable in cash. See also: The Week Ahead In Biotech: ASCO Presentations In The Spotlight Aerpio To Collaborate With Quantum Leap In COVID-19 Drug Trial Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) and Quantum Leap Healthcare announced an agreement to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of ARDS in adult patients with moderate-to-severe COVID-19.The stock jumped 38.11% to $1.08 in after-hours trading.I-Mab's Severe COVID-19 Treatment Candidate Found Safe, Well-Tolerated In Phase 1b/2 Study I-Mab ADR (NASDAQ: IMAB) announced interim results from a clinical study of TJM2 in patients with cytokine release syndrome associated with severe COVID-19, with the Part 1 portion of the study evaluating the safety and tolerability of TJM2 in a total of 24 patients who were randomized at a ratio of 1:1:1 to receive either a single dose of 3 mg/kg TJM2, a single dose of 6 mg/kg TJM2 or placebo, administered by intravenous infusion.The company noted that a Data Monitoring Committee that evaluated data from Part 1 of the study concluded that it can commence the Part 2 of the study as planned, indicating TJM2 is safe and well-tolerated in the severe COVID-19 patients.The stock added 3.01% to $24.98 in after-hours trading.New Immunomedics CEO Quits Due To Coronavirus-Related Logistics Issues Immunomedics, Inc. (NASDAQ: IMMU) said CEO Harout Semerjian has decided to step down from his role effective immediately. Semeriian assumed the CEO role April 16 after his predecessor quit in the wake of a CRL for the company's lead antibody-drug conjugate sacituzumab govitecan and accusations regarding a data integrity breach.View more earnings on IBBThe company said the move was precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Semerjian's ability to fully assume his duties as CEO.Dr. Behzad Aghazadeh, executive chairman of Immunomedics, will continue to support the in an executive leadership role going forward, the company said.The stock was down 1.96% to $33.50 in the premarket session. FDA Grants Moleculin's Pre-IND Meeting Request For Coronavirus Drug Candidate, Shares to Resume TradingMoleculin Biotech, Inc., (NASDAQ: MBRX) said the FDA has granted the company's request for a pre-IND meeting to provide guidance regarding its plan to study its drug candidate WP1122 in a clinical trial for patients with COVID-19.The company said it plans to submit its IND application in the second half of the year, contingent on the guidance received from its pre-IND meeting with the FDA.Moleculin said in a separate release that Nasdaq has said its shares, which have been halted since May 4 due to questions regarding accuracy of information in the marketplace about its drug candidate for coronavirus, will begin trading again Thursday.Offerings Iovance Biotherapeutics Inc (NASDAQ: IOVA) said it intends to offer $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by the company.The stock was down 12.05% to $33.50 in Thursday's premarket session.BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) priced its underwritten public offering of 18.71 million shares at $4.50 per share. The company also said it is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3.51 million shares of its common stock at $4.49 per pre-funded warrant.The company expects to raise gross proceeds of $100 million from the offering.The stock was down 7.25% at $4.67 premarket. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) said it intends to offer in an underwritten public offering and subject to market and other conditions, $250 million worth of its common stock. All of the shares are being offered by the company.Arena shares were down 12.45% at $50.90 premarket. Arcus Biosciences Inc (NYSE: RCUS) said it has commenced an underwritten public offering of its common stock. All the shares in the offering will be sold by the company.The stock was down 1.29% at $26.70 premarket Thursday.On The Radar Earnings * Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close) * Geron Corporation (NASDAQ: GERN) (after the close)Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • PhaseBio Explodes 82% After-Hours On FDA Nod For Covid-19 Clinical Trial
    SmarterAnalyst

    PhaseBio Explodes 82% After-Hours On FDA Nod For Covid-19 Clinical Trial

    Shares in PhaseBio Pharmaceuticals (PHAS) surged 82% in after-hours trading on Wednesday, after the company announced clearance of its investigational new drug (IND) application by the FDA under its Coronavirus Treatment Acceleration Program (CTAP).PhaseBio’s “VANGARD” trial will assess the efficacy and safety of its PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome. Approximately 210 patients will be targeted to be enrolled at approximately 20 sites across the US. The primary endpoint will measure days alive and free of respiratory failure.The patients will be treated with PB1046, a novel, once-weekly, subcutaneously-injected vasoactive intestinal peptide (VIP) receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems. VIP is a neurohormone known to have anti-inflammatory effects, and importantly, has also been observed to have potent bronchodilatory and immunomodulatory effects in the respiratory system.PhaseBio now expects to begin dosing patients by the end of June and is targeting to report trial results late in the fourth quarter of 2020. Based on feedback from the FDA, PhaseBio believes that positive, clearly interpretable and clinically meaningful results from this trial may enable PhaseBio to submit a Biologics License Application.“Physicians are in desperate need of new options to treat COVID-19 patients facing rapid deterioration of lung function and before progressing to a ventilator,” said John Lee, CMO at PhaseBio. “Early mitigation by PB1046 of the effects of inflammatory cytokines that can cause acute lung injury, is a promising strategy that could prevent patients from declining to the point where they require mechanical ventilation and help alleviate the strain on critical care infrastructure that we’re witnessing.”Indeed, analysts have a firmly bullish outlook on PHAS with 4 recent buy ratings, no holds and no sells, giving it a Strong Buy consensus. The average analyst price target stands at $12.75 (188% upside potential). (See PhaseBio stock analysis on TipRanks).Related News: Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July Merck CEO Casts Doubt On ‘Very Aggressive’ Covid-19 Vaccine Timeline Regeneron Announces Secondary Offering Pricing At $515/Share More recent articles from Smarter Analyst: * 5-Star Analyst Pounds the Table on Roku Stock * Efgartigimod's Positive Data Is Good News for Momenta’s Nipocalimab * Elon Musk Reaps Payout Worth $775M, As Analyst Admits Tesla Is ‘Turning A Corner’ * Costco Pulls Back On Earnings; Top Analyst Sees Buying Opportunity

  • PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates

    PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -26.83% and -14.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights
    Business Wire

    PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights

    PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights

  • Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

    PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PhaseBio Pharmaceuticals, Inc. (PHAS) Shares March Higher, Can It Continue?
    Zacks

    PhaseBio Pharmaceuticals, Inc. (PHAS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in PhaseBio Pharmaceuticals, Inc. (PHAS).

  • Easy Come, Easy Go: How PhaseBio Pharmaceuticals (NASDAQ:PHAS) Shareholders Got Unlucky And Saw 74% Of Their Cash Evaporate
    Simply Wall St.

    Easy Come, Easy Go: How PhaseBio Pharmaceuticals (NASDAQ:PHAS) Shareholders Got Unlucky And Saw 74% Of Their Cash Evaporate

    PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) shareholders should be happy to see the share price up 21% in the last...

  • GlobeNewswire

    PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

    Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for.

  • GlobeNewswire

    PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference

    MALVERN, Pa. and SAN DIEGO, Feb. 26, 2020 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswire

    PhaseBio Appoints Alex C. Sapir to Board of Directors

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Alex C. Sapir to its board of directors. Additionally, Bibhash Mukhopadhyay, Ph.D., has stepped down from his role as a director. “Alex’s deep commercial expertise gained from his time at United Therapeutics and GSK coupled with his experience leading Dova Pharmaceuticals into becoming a fully integrated commercial-stage company will be an invaluable addition to our already strong board,” said Jonathan P. Mow, chief executive officer of PhaseBio.

  • GlobeNewswire

    PhaseBio Announces European Regulatory Update for PB2452

    PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase.

  • Wall Street Pros: These 3 Stocks Can Double Next Year
    TipRanks

    Wall Street Pros: These 3 Stocks Can Double Next Year

    Let’s not complicate matters. Broken down into the most basic elements, it’s all very simple: investors want to put their hard earned cash in a place where they will return to after a period of time, and find that, viola! There is more money in said place than they had initially put in.But what is the best way to go about it? There are countless options, for sure, but as anyone, in any field will tell you, listening to the pros’ advice is one well-trodden, tried and tested path.TipRanks tracks the recommendations of over 6,000 such pros pounding the investing pavement of Wall Street on a daily basis. With this in mind, we used the platform to take a look at 3 tickers the experts on the Street think could potentially double in value over the next year. Let’s jump right in.Phasebio Pharmaceuticals Inc. (PHAS)If you’re looking to double your investment over a 12-month period, then the healthcare industry is a good place to begin your search. The volatile sector often sees biotechs double their value in a week, or even a day, never mind a year. The sector comes, though, with added risk attached to it, as what can be sent soaring majestically following positive data or regulatory approval can also be dumped unceremoniously by investors, should negative news make the headlines.With this in mind, we turn to Phasebio Pharmaceuticals. This micro-cap is focused on developing novel therapies for orphan diseases with a strong emphasis on cardiopulmonary indications.The company’s lead candidate is PB2452, a monoclonal antibody antigen-binding fragment intended to reverse the antiplatelet effects of AstraZeneca's blood thinner Brilinta. The drug is currently in a Phase 2b trial, with plans to initiate a pivotal Phase 3 trial in this year’s first quarter. The trial will support a Biologics License Application (BLA) for PB2452 in both major bleeding and urgent surgery indications.Following a successful Phase 1 trial last year, the FDA granted the drug breakthrough therapy designation (BTD) status. If the rest of the trials go well, PB2452 should hit the market by no later than 2022.Citigroup’s Joel Beatty believes Phasebio stock is “overly cheap”. The analyst thinks Phasebio is the most undervalued stock in Citi’s SMid-biotech coverage universe. “Although we project that Phase 3 results for PB2452 will come in 2H21 (beyond the current cash runway into ~1Q21), we see potential for enrollment updates throughout 2021 to provide some upside,” he said.Bottom line? Beatty maintained his Buy rating on Phasebio, along with a price target of $25. This implies potential upside of a massive 357%. (To watch Beatty’s track record, click here)The rest of the Street is hardly any less enthusiastic. 6 Buy ratings add up to a Strong Buy consensus rating. The average price target hits $21, implying potential gains of a massive 274%. (See Phasebio price targets and analyst ratings on TipRanks) GlycoMimetics (GLYC)Let’s stay in the biotech sector and look at the dramatic effect disappointing trial results can have on a stock.In August last year, biotech GlycoMimetics licensee Pfizer reported negative results from the Phase 3 RESET trial of Rivipansel, which demonstrated that it failed to meet the primary endpoint of the study. What happened next, you ask? Shares of GLYC tumbled in a day, shedding 69% of their value. Ouch. The share price slowly clawed its way out of the doldrums throughout the rest of the year, but so far in 2020, the stock is down by 17%.Nevertheless, Stifel Nicolaus’ Stephen Willey is a fan of GLYC. The 5-star analyst claims the oncology-focused company’s candidate for the treatment of patients with acute myeloid leukemia (AML), uproleselan/GMI-1687 (formerly GMI-1271), is a “highly-differentiated and potentially best-in-class therapy for these limited-option patients.” He argues that the delay of Phase 3 top-line results has no bearing on his longer-term outlook for the drug.According to Willey, the Phase 1/2 uproleselan data in relapsed/refractory and newly-diagnosed AML, which demonstrated a marked improvement in both the magnitude and depth of patient responses and the mitigation of chemotherapy-induced toxicity, bodes well for the candidate’s prospects.Additionally, Willey feels the current valuation ignores other earlier-stage pipeline opportunities. Taking all this into consideration, then, Willey reiterated a Buy rating and $14 price target on the biotech. Should his thesis play out, investors will pocket a hefty 220% gain over the next year. (To watch Willey’s track record, click here)Similarly, the majority of the Street takes a bullish approach when it comes to GLYC. Out of 5 analysts tracked over the last three months, 4 recommend a Buy while one suggests a Hold. At the average price target of $11.50, investors will take home a 161% gain should the figure be met in the months ahead. (See GlycoMimetics price targets and analyst ratings on TipRanks) Chiasma (CHMA)The third ticker on our list is a fellow micro-cap from the biotech space. Chiasma’s focus is on improving the lives of patients suffering from rare and serious chronic diseases. Its goal is to develop oral medications that are currently only available as injections through the use of its Transient Permeability Enhancer (TPE) technology platform.The company is developing octreotide capsules, known as Mycapssa, for the treatment of adult patients with acromegaly, a disorder that results from excess growth hormone. Symptoms of the disease can include the enlargement of the hands and feet, along with the forehead, jaw and nose, possibly leading to type 2 diabetes, sleep apnea and high blood pressure. The condition is extremely rare and affects about 6 out of 100,000 people.Chiasma received the dreaded CRL (complete response letter) for the drug in April 2016, which cited the need for another clinical trial. It resubmitted its Mycapssa (octreotide) application in December, which the FDA has accepted for review. A decision on the application is expected mid-year. If all goes well, commercial launch should ramp up in Q4.Piper Sandler’s Edward Tenthoff is confident that Mycapssa will receive US approval, noting that manufacturing preparation is underway ahead of its potential launch. Not to mention the 5-star analyst believes that Chiasma remains on course to report top-line data from its Phase 3 MPOWERED study in Europe during Q4 to support EMA approval.As a result, Tenthoff kept his Overweight rating on Chiasma along with a price target of $11 as is. Investors will be celebrating returns of a hefty 123% should the target be met. (To watch Tenthoff’s track record, click here)The chronic disease fighter’s Strong Buy consensus rating breaks down into Buy ratings only – 4, as it happens. The average price target of $12.75 implies potential upside of 161%. (See Chiasma stock analysis on TipRanks)

  • Benzinga

    The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

  • GlobeNewswire

    PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a patient who received more than 18 months of treatment with PB1046, the company’s first-in-class, sustained-release vasoactive intestinal peptide (VIP) analogue being evaluated for the treatment of patients with pulmonary arterial hypertension (PAH). The data, which were presented at the 14th Pulmonary Vascular Research Institute (PVRI) World Congress held in Lima, Peru, from January 30th through February 2nd 2020, demonstrate clinically-meaningful improvements in all of the hemodynamic parameters assessed, which were sustained for up to three months after the last dose was administered.

  • Rock star Growth Puts PhaseBio Pharmaceuticals (NASDAQ:PHAS) In A Position To Use Debt
    Simply Wall St.

    Rock star Growth Puts PhaseBio Pharmaceuticals (NASDAQ:PHAS) In A Position To Use Debt

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

  • Benzinga

    The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...

  • GlobeNewswire

    PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

    MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.

  • American City Business Journals

    Shares of Malvern life sciences firm skyrocket on funding deal worth up to $120M

    Shares of a Malvern pharmaceutical firm soared on Friday as the company announced a financing and co-development deal worth up to $120 million. PhaseBio will work with Pleasanton, Calif.-based SFJ Pharmaceuticals on the development of one of its lead drug candidates, PB2452. The funding will be used for development expenses and to help with regulatory approvals outside of the U.S. SFJ will fund up to $90 million through the end of 2021, and up to an additional $30 million based on PhaseBio meeting specific clinical milestones.

  • GlobeNewswire

    PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor. SFJ Pharmaceuticals is a global drug development company backed by Blackstone Life Sciences and Abingworth. The collaboration between SFJ and PhaseBio will support the global development of PB2452, which is designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

  • Hedge Funds Have Never Been This Bullish On PhaseBio Pharmaceuticals, Inc. (PHAS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On PhaseBio Pharmaceuticals, Inc. (PHAS)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • GlobeNewswire

    PhaseBio to Present at Stifel 2019 Healthcare Conference

    MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.